These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3429337)

  • 41. New penem compounds with 5'-substituted pyrrolidinylthio group as a C-2 side chain; comparison of their biological properties with those of carbapenem compounds.
    Sunagawa M; Matsumura H; Inoue T; Fukasawa M
    J Antibiot (Tokyo); 1992 Apr; 45(4):500-4. PubMed ID: 1592682
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carbapenems in the USA: focus on doripenem.
    Lister PD
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):793-809. PubMed ID: 17914914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and antibacterial activity of 1-substituted-methyl carbapenems.
    Sendo Y; Kii M; Sakanoue M; Motokawa K; Kimura Y
    Chem Pharm Bull (Tokyo); 1992 Sep; 40(9):2410-8. PubMed ID: 1446363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [In vitro antibacterial activities of carbapenems against clinical isolates].
    Murase M
    Jpn J Antibiot; 1999 Nov; 52(11):667-79. PubMed ID: 10659443
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I.
    Fukasawa M; Sumita Y; Harabe ET; Tanio T; Nouda H; Kohzuki T; Okuda T; Matsumura H; Sunagawa M
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1577-9. PubMed ID: 1510457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis of several new carbapenem antibiotics.
    Ohtani M; Watanabe F; Narisada M
    J Antibiot (Tokyo); 1985 May; 38(5):610-21. PubMed ID: 4019310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Syntheses and biological properties of new 8-fluorocarbapenem derivatives.
    Watanabe A; Sakamoto M; Fukagawa Y; Yoshioka T
    Chem Pharm Bull (Tokyo); 1991 Feb; 39(2):335-40. PubMed ID: 2054857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].
    Hikida M; Terashima S; Sato Y; Okamoato R; Inoue M
    Jpn J Antibiot; 2001 Nov; 54(11):571-9. PubMed ID: 11828603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
    Gimeno C; Cantón R; García A; Gobernado M;
    Rev Esp Quimioter; 2010 Sep; 23(3):144-52. PubMed ID: 20844845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative in vitro activity of imipenem against gram-positive and gram-negative aerobic bacteria from clinical isolates.
    Bastianini L; Sposini T; Bartoli A; Marconi P
    Microbiologica; 1988 Apr; 11(2):137-42. PubMed ID: 3165489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Research on new beta-lactam antibiotics; penem and carbapenem].
    Sugimura Y; Hiraoka T
    Yakugaku Zasshi; 1987 Mar; 107(3):175-91. PubMed ID: 3298614
    [No Abstract]   [Full Text] [Related]  

  • 55. Synthesis and antimicrobial properties of S-substituted derivatives of 2-thiouracil.
    Wyrzykiewicz E; Bartkowiak G; Nowakowska Z; Kedzia B
    Farmaco; 1993 Jul; 48(7):979-88. PubMed ID: 8397680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the in vitro activity of meropenem and doripenem against Pseudomonas aeruginosa and multidrug-resistant Enterobacteriaceae.
    Van Gasse N; Vermeiren S; Jeurissen A
    Acta Clin Belg; 2010; 65(6):451. PubMed ID: 21268965
    [No Abstract]   [Full Text] [Related]  

  • 57. Synthesis and in vitro activity of novel quaternary ammonium carbapenems: 2-pyridiniopropyl and 1-pyridinioethyl carbapenems.
    Ueda Y; Vinet V
    J Antibiot (Tokyo); 1992 Jun; 45(6):940-53. PubMed ID: 1500362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imipenem: morphological changes and lethal effects on Pseudomonas aeruginosa.
    Carlone NA; Ferrero M; Cuffini AM; Cavallo R
    Drugs Exp Clin Res; 1987; 13(10):623-9. PubMed ID: 3123190
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.